These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

130 related articles for article (PubMed ID: 17269156)

  • 41. Pharmaceutical patent settlements: the antitrust risks.
    Balto DA
    Food Drug Law J; 2000; 55(3):321-41. PubMed ID: 11824464
    [No Abstract]   [Full Text] [Related]  

  • 42. Branded drug reformulation: the next brand vs. generic antitrust battleground.
    Amoresano GV
    Food Drug Law J; 2007; 62(1):249-56. PubMed ID: 17444032
    [No Abstract]   [Full Text] [Related]  

  • 43. Intellectual property. Fixing the legal framework for pharmaceutical research.
    Knowles SM
    Science; 2010 Feb; 327(5969):1083-4. PubMed ID: 20150445
    [No Abstract]   [Full Text] [Related]  

  • 44. Global trends in the pharmaceutical industry.
    Albers-Schönberg G
    P R Health Sci J; 2002 Jun; 21(2):85-9. PubMed ID: 12166029
    [No Abstract]   [Full Text] [Related]  

  • 45. The interaction between intellectual property and drug regulatory systems: global perspectives.
    Madden EA
    IDrugs; 2007 Feb; 10(2):116-20. PubMed ID: 17285464
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Prescription drug pushers. Patents and ads are the big reasons pills are priced like perfume and caviar.
    Sherrid P
    US News World Rep; 2000 Oct; 129(17):40-2. PubMed ID: 11184929
    [No Abstract]   [Full Text] [Related]  

  • 47. Intellectual property. Balancing innovation and access: patent challenges tip the scales.
    Higgins MJ; Graham SJ
    Science; 2009 Oct; 326(5951):370-1. PubMed ID: 19833944
    [No Abstract]   [Full Text] [Related]  

  • 48. Patent alert.
    Noprman P; Whelan C; Press N
    IDrugs; 2003 Dec; 6(12):1198-1204. PubMed ID: 14712832
    [No Abstract]   [Full Text] [Related]  

  • 49. [The patent is "engine" in drug development].
    Bergström R
    Lakartidningen; 2008 Mar 5-11; 105(10):752. PubMed ID: 18422246
    [No Abstract]   [Full Text] [Related]  

  • 50. Fine print TRIPS up multinational and Indian companies.
    Frantz S
    Nat Rev Drug Discov; 2005 Feb; 4(2):94-5. PubMed ID: 15759327
    [No Abstract]   [Full Text] [Related]  

  • 51. The response to health care reform by the pharmaceutical industry.
    Krulwich AS
    Food Drug Law J; 1995; 50(1):1-22. PubMed ID: 10342983
    [No Abstract]   [Full Text] [Related]  

  • 52. Delaying generic competition--corporate payoffs and the future of Plavix.
    Shuchman M
    N Engl J Med; 2006 Sep; 355(13):1297-300. PubMed ID: 17005945
    [No Abstract]   [Full Text] [Related]  

  • 53. Pfizer slashes R&D.
    Cressey D
    Nature; 2011 Feb; 470(7333):154. PubMed ID: 21307908
    [No Abstract]   [Full Text] [Related]  

  • 54. AIDS drugs. Brazil, Thailand override big pharma patents.
    Cohen J
    Science; 2007 May; 316(5826):816. PubMed ID: 17495145
    [No Abstract]   [Full Text] [Related]  

  • 55. A vision of the pharmaceutical industry.
    Muñio S
    Methods Find Exp Clin Pharmacol; 1998; 20 Suppl A():5-9. PubMed ID: 9800720
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Oseltamivir becomes plentiful--but still not cheap.
    Enserink M
    Science; 2006 Apr; 312(5772):382-3. PubMed ID: 16627733
    [No Abstract]   [Full Text] [Related]  

  • 57. Policy on 180-day marketing exclusivity for drugs marketed under abbreviated new drug applications; clarification--FDA. Clarification.
    Fed Regist; 1997 Nov; 62(229):63268-9. PubMed ID: 10177950
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Overview of the Hatch-Waxman Act and its impact on the drug development process.
    Mossinghoff GJ
    Food Drug Law J; 1999; 54(2):187-94. PubMed ID: 11758572
    [No Abstract]   [Full Text] [Related]  

  • 59. Statin utilisation--recognising the role of the invisible hand.
    Minhas R
    Int J Clin Pract; 2007 Jan; 61(1):3-6. PubMed ID: 17229171
    [No Abstract]   [Full Text] [Related]  

  • 60. Indian generics companies go on spending spree.
    Jayaraman KS
    Nat Rev Drug Discov; 2005 Aug; 4(8):616-7. PubMed ID: 16106583
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.